Trial Profile
A prospective randomized controlled study on Suppression of Prostate Cancer by naftopidil (SNAP)
Status:
Active, no longer recruiting
Phase of Trial:
Phase IV
Latest Information Update: 01 Jul 2022
Price :
$35
*
At a glance
- Drugs Naftopidil (Primary)
- Indications Prostate cancer
- Focus Therapeutic Use
- Acronyms SNAP
- 28 Jun 2022 Status changed from recruiting to active, no longer recruiting.
- 27 Dec 2021 Planned number of patients changed from 1100 to 1200.
- 02 Dec 2016 New trial record